On August 10, 2020 Dragonfly Therapeutics, Inc. ("Dragonfly" or the "Company"), reported that Bristol Myers Squibb ("BMS") has licensed its fourth TriNKET immunotherapy drug candidate from Dragonfly (Press release, Dragonfly Therapeutics, AUG 10, 2020, View Source [SID1234563377]). Since the original 2017 collaboration focusing on hematology malignancies, the companies have agreed two additional collaborations across solid tumors, and autoimmune disease.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are impressed with the quality of candidates developed using Dragonfly’s TriNKET technology," said Rupert Vessey, FRCP, DPhil, President of Research and Early Development, Bristol Myers Squibb. "In just three years, Dragonfly delivered four drug candidates to BMS, a remarkable pace of development. During that time, we have assessed Dragonfly’s TriNKET drug candidates in both cancer and autoimmune indications, and have built three collaborations together. We continue to be encouraged by the potential treatment options for patients offered by harnessing the power of NK cells."

"We have had a very productive collaboration with BMS and are pleased with both the speed of our development efforts and the continuing validation of our platform that this opt-in decision by BMS represents," said Dragonfly CEO Bill Haney. "As we advance our internal programs, including our clinical stage TriNKET DF-1001 and IL12 cytokine DF-6002, we look forward to strong continued collaboration with BMS to bring potential new NK-cell based treatment options to patients with cancer, autoimmune disease, and neurological conditions."